Altos Labs
Altos Labs is a biotechnology company focused on cellular rejuvenation programming to reverse disease, injury, and age-related disabilities.
Secondary Market Price
How Altos Labs Measures Up
To help you manage your Altos Labs equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series C
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Altos Labs's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Altos Labs Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Altos Labs's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Altos Labs is a biotechnology company focused on the biology of cellular rejuvenation. The company's stated mission is to restore cell health and resilience to reverse disease, injury, and disabilities. It operates as a community of scientists and clinicians from both academic and industrial backgrounds, with research facilities in the San Francisco Bay Area, San Diego, and Cambridge, UK. Founded in 2021, Altos Labs launched with significant financial backing, including a Series A funding round of $3 billion announced on February 1, 2021.
The company is actively advancing its research through computational biology and artificial intelligence. Its Institute of Computation team recently won an award for a generative perturbation-prediction model, and the company presented research at NeurIPS 2025 on a benchmarking platform for predicting cellular responses to perturbations. Another project, scGeneScope, was developed in collaboration with Microsoft Research to test models using paired single-cell RNA-seq and image datasets. To further its goal of turning research into clinical applications, Altos Labs recently appointed Dr. Joan Mannick as Chief Medical Officer and Head of Product Development to oversee the translation of its science into potential therapies.
- Jeff Bezos
- Yuri Milner
- ARCH Venture Partners
- Foresite Capital
- Altitude Life Science Ventures
- Co-Founder, Hal Barron
- Co-Founder, Rick Klausner
- Co-Founder, Hans Bishop
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Altos Labs worth joining?
Deciding whether to join a company like Altos Labs depends on its growth prospects and how its mission aligns with your career goals. Tools like Prospect can help you model the potential value of your equity offer to make a more informed decision.
What should I do with my Altos Labs stock?
Managing private company stock involves complex financial and tax decisions that depend on your personal circumstances and the company's trajectory. Platforms like Prospect offer customized strategies for exercising options and managing your shares to maximize their value.
Can you sell Altos Labs stock?
As a private company, shares in Altos Labs are not publicly traded and can typically only be sold during company-approved liquidity events like a tender offer or on a secondary market. Navigating these sales requires careful planning to optimize timing and tax implications, which is where specialized tools can be beneficial.
How can I find the value of my Altos Labs stock?
The value of private stock is typically determined by a 409A valuation or the price per share in the latest funding round. For a more forward-looking analysis, platforms like Prospect use predictive models to help you forecast the potential future value of your equity.
What is Altos Labs's equity worth?
The total worth of Altos Labs's equity is based on its most recent private valuation, which is not public information. To understand what your specific holdings might be worth after taxes and exercise costs, you can use financial modeling tools designed for startup equity.
What is Altos Labs's stock ticker symbol?
Altos Labs is a private company, so it does not have a stock ticker symbol as it is not traded on a public stock exchange. Ticker symbols are assigned to companies only when they undergo an Initial Public Offering (IPO).
Can I buy or sell Altos Labs stock?
Selling stock in a private company like Altos Labs is generally restricted to specific liquidity events, while buying shares is typically reserved for accredited investors during formal funding rounds. Employees looking to manage their equity can use platforms like Prospect to prepare for selling opportunities and understand their holdings.
What is the criteria to buy or invest in Altos Labs stock?
Investing in a private company like Altos Labs is typically limited to venture capital firms and accredited investors who meet specific wealth and income thresholds defined by financial regulators. These opportunities are not generally available to the public.
